Vegetable protein, providing 80% of protein requirements in Third World Countries, can be quantitatively adequate but qualitatively inadequate in protein content. Supplementation with limiting amino acids (AA's) is possible and might aid intrauterine offspring development. In the present experiments 21 Sprague Dawley rats were impregnated and groups of 7 begun on one of 3 diets: A) bread, B) bread + lysine and threonine, or C) lab chow. Weights of all offspring at birth were lower (p< .001) in group A (5.64 2 0.529) compared to groups B (6.39 5 0.88g) or C (6.49 5 0.349). Two newborns from each of the 7 litters in each of the 3 groups were randomly selected for further brain studies. Reports on incidence of central nervous system (CNS) sequelae in term SGA infants have been generally encouraging. This paper presents results of a follow-up study of preterm SGA infants (birthweight >SD below mean) born at 33-36 wk. gestation. 41 infants meeting these criteria were admitted to the neonatal unit in 1974, 75. 30135 survivors were followed for at least 2 yrs and were tested by the Bayley Developmental Scales at 18 mo from term. The Bayley scores were low -mean 83215 -with 12 (40%) scoring<80. Cerebral palsy occurred in 6 children, 5 of whom were diplegic. 4 of the 6 scored <80 on the Bayley.
S e r i a l serum-free PAS, namely spermine (SPM) and s p e m i d i n e (SPD' were determined from serum sample a l i q u o t s by radioiinnunoassay. A l l p a t i e n t s had e l e v a t e d SPD values (mean peak value o f 2.06 nanomol/ml ) which d e c l i n e d r a p i d l y t o a post-admission value o f 0.45 nanomol/rnl i n t h e 3 s u r v i v i n g c h i l d r e n . Highest SPD value (4.20 nanomol/ml ) was observed i n t h e p a t i e n t w i t h t h e most severe n e u r o l o g i c a l score (111) on admission. SPM l e v e l s , by c o n t r a s t , were much lower and t h e r e was a 1-2 day d e l a y i n SPM peak development i n t h e 3 s u r v i v i n g c h i l d r e n . C l i n i c a l improvement p a r a l l e l e d t h e d e c l i n e i n serum PAS. PA administerec I . V . t o man causes prompt and p e r s i s t e n t vomiting. S p e c i f i c PA b i n d i n g s i t e s have been i d e n t i f i e d on animal b r a i n c e l l membranes. SPM has been demonstrated t o markedly reduce oxygen consumption by b r a i n t i s s u e . I n v i t r o Na, K-ATPase a c t i v i t y i s a l s o depressed by PA a d d i t i o n . Parenteral PA doses t o experimental animals may cause somnolence, a t a x i a , coma and death. Reports on incidence of central nervous system (CNS) sequelae in term SGA infants have been generally encouraging. This paper presents results of a follow-up study of preterm SGA infants (birthweight >SD below mean) born at 33-36 wk. gestation. 41 infants meeting these criteria were admitted to the neonatal unit in 1974, 75. 30135 survivors were followed for at least 2 yrs and were tested by the Bayley Developmental Scales at 18 mo from term. The Bayley scores were low -mean 83215 -with 12 (40%) scoring<80. Cerebral palsy occurred in 6 children, 5 of whom were diplegic. 4 of the 6 scored <80 on the Bayley.
Bayley scores were not related to either the degree of intrauterine head growth restriction or the rate of early postnatal head growth. They did not correlate with gestation, complications of pregnancy/delivery, asphyxia or hypoglycemia. However, 6 of the 12 with Bayley (80 had asphyxia or hypoglycemia that was accompanied by seizures or apnea. Only 1/18 with Bayley >80 was so affected (p-(0.02).
The results show that, unlike the full term SGA, the preterm SGA is at a high risk for serious CNS handicap and that this risk increases if asphyxia or hypoglycemia is accompanied by seizures or apnea.
Carbamazepine ( T e g r e t o l r ) i s used e f f e c t i v e l y i n t h e t r e a tment o f s e i z u r e d i s o r d e r s and t r i g e m i n a l n e u r a l g i a . Reported s i d e e f f e c t s a r e p r i m a r i l y n e u r o l o g i c a l , occur i n f r e q u e n t l y and r a r e l y r e q u i r e d i s c o n t i n u a t i o n o f t h e drug. We have cared f o r 3 c h i l d r e n i n whom 4 episodes o f d y s t o n i a and opisthotonus occ u r r e d i n a s s o c i a t i o n w i t h carbamazepine use. The p a t i e n t s , a 2 y r . o l d w i t h microcephaly, a 3 y r . o l d w i t h c e r e b r a l dysgenes i s and a 5 y r . o l d w i t h s p a s t i c quadraplegia; a l l had s e i z u r e s r e q u i r i n g m u l t i p l e a n t i c o n v u l s a n t s . I n a l l 3 p a t i e n t s carbamazepine was i n t r o d u c e d and g r a d u a l l y increased t o a maximum o f 25 mg/kg/d.
Symptoms began 2-3 weeks a f t e r i n t r o d u c t i o n o f therapy and subsided w i t h i n 3 weeks a f t e r d i s c o n t i n u a t i o n .
I n one case a 2nd course o f carbamazepine r e s u l t e d i n a r e t u r n o f t h e dystonia. No hematologic o r h e p a t i c a b n o r m a l i t i e s were noted. Blood l e v e l s o f c o n c u r r e n t l y administered a n t i c o n v u lsants, i n c l u d i n g phenytoin, were w i t h i n t h e r a p e u t i c range. A s i n g l e carbamazepine blood l e v e l obtained d u r i n g one o f t h e episodes was a l s o t h e r a p e u t i c (5.1 mcg/ml). E a r l y r e p o r t s of carbamazepine's b e n e f i c i a l e f f e c t i n some d y s t o n i c syndromes have n o t been supported by f u r t h e r c l i n i c a l t r i a l s . I t has a l s o been r e p o r t e d t o enhance t h e r e l e a s e o f ADH. Our o b s e r v a t i o n o f i n c a p a c i t a t i n g b u t r e v e r s i b l e d y s t o n i a r a i s e s f u r t h e r q u e s t i o n about t h e e f f e c t s o f carbamazepine on t h e c e n t r a l nervous system. The need e x i s t s f o r an awareness o f t h i s c o m p l i c a t i o n i n p h y s i c i a n s c a r i n g f o r n e u r o l o g i c a l l y handicapped c h i l d r e n .
lupstate Med. ctr., ~y r . , N.Y. Recurring cerebrovascular disease is extremely rare in children. Moya-moya (supraclinoid carotid stenosis with multiple cerebral telangiectasias) may be the vascular pathology underlyinc many such instances. Initially described as a congenital anomaly in the Japanese literature, it is uncommonly recognized in occidentals. We have cared for two Caucasian children in whom several factors strongly suggest moya-moya can be an acquired process and in whom the course was much more benign that commonly described. A 4% year old boy with transposition of the great vessels developed a right hemiparesis after a total corrective operation. Six and one-half years later he had a subarachnoid hemorrhage (SAH). Computed tomography and cerebral angiography demonstrated a left frontal intracerebral hematoma and subadjacent brain atrophy and moya-moya. He has been well for 2$ years A girl with sickle cell disease had a right hemiparesis at age 8. Six years later she had a SAH. Computed tomography and cerebral angiography demonstrated left parietal atrophy, intracerebral hematoma, and moya-moya. She has been normal for 2 years. Presentation of moya-moya in children as SAH has been noted only once previously. Moreover, our two children had a basic disease process not associated with cerebral telangiectasia but occasionally associated with cerebrovascular occlusive disease. The demonstration of moya-moya six years after a single presumably vascular occlusive event strongly suggests moya-moya can be a tenuous physiologic compensation to an acquired phenomenon.
VALPROIC ACID I N THE TFEATMENT OF INTRACTABLE SEIZURE Robert P Cruse; G: ra; d Erenber-9: A: Davld Rothner; and Charles Henry Spon. by W i l l i a m Michener) The C l i n i c Founda ~l e c t r o e n c e p h a l o g r a p h y , Cleveland. I 45 p a t i e n t s w i t h i n t r a c t a b l e seizures a r e being t r e a t e d w i t h a iew a n t i c o n v u l s a n t , v a l p r o i c a c i d (VPA). Two separate p r o t o c o l s sre being f o l l o w e d . VPA was i n i t i a l l y added t o previous drugs.
The f i r s t p r o t o c o l i n v o l v e s 19 p a t i e n t s w i t h simple o r complex ~b s e n c e seizures. Maximum VPA dose i s 60 mgm/Kgm/day. 6 h r EEGs vere o b t a i n e d i n i t i a l l y , a f t e r two weeks o f placebo and a f t e r 10 reeks o f VPA. EEG a n a l y s i s included t h e number and d u r a t i o n o f 2 l e c t r i c a l seizures. A l l p a t i e n t s show c l i n i c a l improvement. 14 lave a 75-100% r e d u c t i o n i n c l i n i c a l seizures. 5 a r e s e i z u r e 'ree; none on l e s s t h a n 60 mgm/Kgm/day. I n 6, c l i n i c a l improvel e n t cannot be c o r r e l a t e d w i t h t h e degree o f EEG improvement.
The second p r o t o c o l i n v o l v e s 26 p a t i e n t s w i t h mixed s e i z u r e types., Maximum VPA dose i s 30 mgm/Kgm/day. Routine EEGs were lone i n i t i a l l y and a f t e r reaching s t a b l e maximum dosage, 13 > a t i e n t s a r e improved. 7 have a 75-1004: r e d u c t i o n i n c l i n i c a l seizure frequency and 6 a 33-74% r e d u c t i o n . 3 p a t i e n t s a r e n o t improved.
EEGs show no s i g n i f i c a n t change. No p a t i e n t i s s e izure f r e e a t a 30 mgrn/Kgm/day dosage.
VPA was e f f e c t i v e a g a i n s t a v a r i e t y o f i n t r a c t a b l e s e i z u r e :ypes.
There was no c o n s i s t e n t c o r r e l a t i o n between c l i n i c a l and IEG improvement. No serious s i d e e f f e c t s o r exacerbations o f s e i z u r e s occurred.
